Document is current
Any future updates will be listed below
-
Authors
Choi, Jae Eun
Qiao, Yuanyuan https://orcid.org/0000-0002-1178-3480
Kryczek, Ilona https://orcid.org/0000-0002-3130-2533
Yu, Jiali
Gurkan, Jonathan https://orcid.org/0000-0002-0149-3463
Bao, Yi
Gondal, Mahnoor https://orcid.org/0000-0002-9419-6758
Tien, Jean Ching-Yi
Maj, Tomasz https://orcid.org/0000-0002-8431-1361
Yazdani, Sahr
Parolia, Abhijit
Xia, Houjun
Zhou, JiaJia
Wei, Shuang
Grove, Sara
Vatan, Linda
Lin, Heng
Li, Gaopeng
Zheng, Yang https://orcid.org/0000-0002-6793-3206
Zhang, Yuping https://orcid.org/0000-0002-8727-5183
Cao, Xuhong
Su, Fengyun
Wang, Rui
He, Tongchen
Cieslik, Marcin
Green, Michael D. https://orcid.org/0000-0003-4951-7118
Zou, Weiping https://orcid.org/0000-0001-7952-3549
Chinnaiyan, Arul M. https://orcid.org/0000-0001-9282-3415
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35 CA231996)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50 CA186786)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (F31 CA26461-01)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 17 August 2023
Accepted: 15 May 2024
First Online: 28 June 2024
Competing interests
: A.M.C. is co-founder and SAB member of LynxDx, Esanik, Medsyn, and Flamingo Therapeutics. A.M.C. serves as a scientific advisor or consultant to EdenRoc, Proteovant, Rebus, and Tempus. W.Z. has served as a scientific advisor or consultant for NGM, CrownBio, Cstone, ProteoVant, Hengenix, NextCure, and Intergalactic. J.E.C., A.M.C., and W.Z. have submitted a patent application with the University of Michigan, Ann Arbor. The remaining authors declare no competing interests.
